SARCULATOR vs CARTOX
Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.
SARCULATOR
This medical tool provides physicians with predictive models for retroperitoneal and extremity sarcoma patients. It estimates overall survival and disease-free survival, serving as an informative resource to enhance physician predictive capabilities.
- Predictive models for sarcoma patients
- Estimates 5-year overall survival
- Estimates 5-year disease-free survival
- Estimates 10-year overall survival
- Estimates cumulative incidence of distant metastasis
- Informative tool for physicians
Read full descriptionHide full description
This app is meant to be used only by physicians and it is not meant to make clinical decisions (the clinical usefulness of the two models has not been tested) but to be used as an informative tool to improve the predictive capability of a physician. Two kinds of predictions are possible: - RPS: 5-year overall survival (OS) and 5-year disease-free survival (DFS) in primary resected retroperitoneal sarcoma (RPS) patients. . - ESTS: 5- and 10-year overall survival (OS) and cumulative incidence of distant metastasis (CCI of DM) in primary resected extremity STS patients.
CARTOX
This medical app aids clinicians in assessing and managing toxicities associated with cellular therapies, including Cytokine Release Syndrome (CRS) and Immune effector Cell-Associated Neurotoxicity Syndrome (ICANS). It provides grading methods and treatment recommendations for healthcare professionals caring for patients undergoing immune effector cell therapy.
- Toxicity grading
- CRS assessment
- ICANS assessment
- Treatment recommendations
- Antimicrobial prophylaxis guidance
Read full descriptionHide full description
Cellular therapies can be associated with unique, acute toxicities which can be severe or even fatal if not identified early and treated appropriately. Cytokine Release Syndrome (CRS), the most commonly observed toxicity can range in severity from low-grade constitutional symptoms to high-grade syndrome associated with life-threatening multi-organ disfunction. Neurotoxicity, originally termed CRES (CAR-Related Encephalopathy Syndrome) and now updated to ICANS (Immune effector Cell-Associated Neurotoxicity Syndrome) is the second most-common adverse even and can occur concurrently with CRS. A multi-disciplinary working group was formed to address safety issues for patients receiving cellular therapy which led to the development of new grading methods and treatment algorithms that have been incorporated into the CARTOX mobile app. The CARTOX mobile app assists with grading toxicities, managing toxicities and assists with recommendations regarding appropriate antimicrobial prophylaxis for patients who have received immune effector cell therapy. Users are more easily able to determine if the patient is having cytokine release syndrome or neurotoxicity and to grade those toxicities. Intended audience: Clinicians (physicians, nurse practitioners, physician assistants, pharmacists, nurses) who treat/care for patients receiving immune effector cells.
Screenshots
Verdict
The clearest difference is rating: CARTOX at 5.0 against SARCULATOR's 4.3. SARCULATOR's advantage is update cadence (every 6 months vs every 20 months) and iOS requirement (15.0 vs 26.4). On price, ratings volume, ads and in-app purchases there is nothing between them.
Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS
Both are free to download. Neither carries in-app purchases, so what you see is what you pay.
CARTOX holds the better App Store score, 5.0 against 4.3. Both are backed by a comparable volume of ratings — 3 and 6 respectively.
SARCULATOR ships an update every 6 months, CARTOX every 20 months. The most recent releases landed on November 19, 2026 and November 18, 2026 respectively.
| Parameter | SARCULATOR | CARTOX |
|---|---|---|
| Price | Free | Free |
| Rating | 4.3 (3 ratings) | 5.0 (6 ratings) — better |
| Positive reviews | — | 100.0% of reviews |
| Number of ratings | 3 | 6 — better |
| Update frequency | Every 6 months — better | Every 20 months |
| Ads | No | No |
| In-app purchases | No | No |
| Monetization | Free | Free |
| Devices | iPhone, iPad, iPod — better | iPhone, iPad |
| Requires iOS | 15.0 — better | 26.4 |
| Further details — not scored | ||
| Size | 29 MB | 6 MB |
| Age rating | 12+ | 17+ |
| Developer | DIGITAL FOREST SRL | MD Anderson Cancer Center |
Customer experience
SARCULATOR
CARTOX
In-app purchases
SARCULATOR
No in-app purchases
CARTOX
No in-app purchases








